Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Events
    • Recent News
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Events
  • Recent News

DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement

Feb 11, 2013

DelMar Pharmaceuticals Announces $1.5 Million Second Closing in Private Placement

Jan 31, 2013

DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies

Jan 25, 2013

Del Mar Pharmaceuticals to Present at 5th Annual Biotech Showcase

Jan 4, 2013

DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting

Nov 15, 2012

DelMar CEO Delivers Keynote Address at International Drug Discovery Science and Technology Conference

Nov 8, 2012

DelMar Pharmaceuticals Expands Collaboration with Guangxi Wuzhou Pharmaceutical Company

Oct 29, 2012

DelMar Pharmaceuticals Named to the “Ready to Rocket” List for the Second Year in a Row

Feb 28, 2012

DelMar Pharmaceuticals to Present New Pre-clinical Data Related to the Mechanism of VAL-083 at the AACR Annual Meeting in April 2012

Feb 7, 2012

DelMar Pharmaceuticals Granted U.S. Orphan Drug Designation for VAL-083 for the Treatment of Glioma

Feb 2, 2012
    • 1...
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    © 2021 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information